Background
Phase III, double-blind, placebo-controlled RCT. 796 patients with first-line mCRPC unselected for HRR gene alterations (all-comers), receiving abiraterone + prednisone as backbone. Olaparib added to abiraterone to test whether PARP inhibition enhances ARPI activity in first-line mCRPC regardless of HRR mutation status. HRR-mutated patients comprised ~28% of enrolled patients.
Interventions and follow up
Arm A: Olaparib 300mg twice daily orally + abiraterone 1000mg/day + prednisone 5mg twice daily
Arm B: Placebo + abiraterone 1000mg/day + prednisone 5mg twice daily
Primary endpoint: Radiographic PFS (rPFS)
mFollow up: 18.4 mo (rPFS primary); 36.9 mo (OS update)
Arm B: Placebo + abiraterone 1000mg/day + prednisone 5mg twice daily
Primary endpoint: Radiographic PFS (rPFS)
mFollow up: 18.4 mo (rPFS primary); 36.9 mo (OS update)
Results
rPFS (all-comers): 24.8 vs 16.6 mo, HR 0.66, P<.001
OS (all-comers): 42.1 vs 34.7 mo, HR 0.81, P=.054 — not statistically significant
rPFS (HRRm subgroup): HR 0.50
rPFS (BRCA-mutated subgroup): HR 0.23
OS (all-comers): 42.1 vs 34.7 mo, HR 0.81, P=.054 — not statistically significant
rPFS (HRRm subgroup): HR 0.50
rPFS (BRCA-mutated subgroup): HR 0.23
Adverse events
Overall: Grade ≥3 AEs 47.2% vs 38.4%; discontinuation due to AEs 13.8% vs 8.0%
Hematologic: Anemia grade ≥3 15.1% vs 3.3%; thrombocytopenia grade ≥3 3.8% vs 1.0%
Vascular: Pulmonary embolism 6.3% vs 4.5%
GI/constitutional: Nausea (any) 39.8% vs 19.3%; fatigue grade ≥3 5.5% vs 3.2%
Hematologic: Anemia grade ≥3 15.1% vs 3.3%; thrombocytopenia grade ≥3 3.8% vs 1.0%
Vascular: Pulmonary embolism 6.3% vs 4.5%
GI/constitutional: Nausea (any) 39.8% vs 19.3%; fatigue grade ≥3 5.5% vs 3.2%
Conclusions
Olaparib + abiraterone improved rPFS versus abiraterone alone in all-comer first-line mCRPC; however, OS did not reach statistical significance (HR 0.81, P=.054), limiting the interpretation of OS benefit. The rPFS benefit was larger in HRR-mutated and especially BRCA-mutated subgroups.
Key Limitations
Key Limitations: OS did not reach statistical significance despite a clinically meaningful HR of 0.81, undermining the clinical certainty of the survival benefit. The unselected all-comer design leads to dilution of effect in HRR-wildtype patients who receive added olaparib toxicity without clear OS benefit. The rPFS benefit in the HRR-wildtype subgroup was modest (HR 0.76). MAGNITUDE (niraparib + abi) similarly showed futility in the HRR-wildtype subgroup. The combination adds meaningful hematologic toxicity and cost in an unselected population.
Clinical Context
FDA approved olaparib + abiraterone for BRCA-mutated first-line mCRPC in 2023 (label narrowed from all-comers to BRCA1/2-mutated based on OS data). The all-comer indication was not supported by the OS results. PROpel, MAGNITUDE, and TALAPRO-2 together established that PARP + ARPI combinations have the greatest benefit in BRCA1/2-mutated first-line mCRPC, while HRR-wildtype patients derive limited benefit. BRCA1/2 tumor testing is now essential at mCRPC diagnosis.
References